期刊文献+

五味子甲素增强奥沙利铂对结直肠癌细胞的杀伤作用 被引量:2

Schizandrin A enhances killing effect of oxaliplatin on colorectal cancer cells
下载PDF
导出
摘要 背景五味子甲素(schizandrin A,SchA)在多种肿瘤中具有抗癌和逆转多药耐药性的作用,但其对奥沙利铂(oxaliplatin,L-OHP)在结直肠癌细胞的作用并不清楚.目的探讨SchA是否能增强L-OHP对结直肠癌细胞的杀伤作用,并分析其机制.方法将结直肠癌细胞分为对照组、SchA处理组、L-OHP处理组和SchA+L-OHP联合处理组.用噻唑蓝(methyl thiazolyltetrazolium,MTT)法检测细胞活力;流式细胞术法检测细胞凋亡;活性氧簇(reactive oxygen species,ROS)探针检测细胞ROS含量;5,5’,6,6’-四氯-1,1’,3,3’-四乙基苯并咪唑羰花青碘化物(1,1’,3,3’-tetraethyl-5,5’,6,6’-tetrachloroimidacarbocyanineiodide,JC-1)探针评估线粒体膜电位变化;Western blot检测B-细胞淋巴瘤-2(B-cell lymphoma 2,Bcl-2)、Bcl-2相关X蛋白(Bcl-2associatedXprotein,Bax)、细胞色素c(cytochrome c,Cytc)和劈开的半胱氨酸蛋白酶-3(cleavedcysteine proteinase-3,cleaved caspase-3)的表达.结果与L-OHP处理组比较,SchA+L-OHP联合处理组的结直肠癌细胞的细胞活力明显降低,细胞凋亡明显增加.SchA能增强L-OHP导致的结直肠癌细胞内ROS蓄积、Bax和cleaved caspase-3表达、线粒体Cyt c释放,并降低Bcl-2表达.结论SchA增强L-OHP对结直肠癌细胞的杀伤作用,其机制可能与增强细胞内ROS蓄积以及促凋亡相关蛋白表达相关. BACKGROUND Schizandrin A(SchA) has anticancer and multidrug resistance-reversing effects in a variety of tumors,but its effect on oxaliplatin(L-OHP) in colorectal cancer cells is not clear.AIM To investigate whether SchA can enhance the killing effect of L-OHP on colorectal cancer cells,and to analyze the possible mechanism involved.METHODS Colorectal cancer cells were divided into control group,SchA treatment group,L-OHP treatment group,and SchA + L-OHP treatment group.Cell viability was detected by MTT assay.Cell apoptosis was detected by flow cytometry.The contents of reactive oxygen species(ROS) in cells was detected using a ROS probe.Mitochondrial membrane potential was evaluated by using the 1,1’,3,3’-tetraethyl-5,5’,6,6’-tetrachloroimidacarbocyanine iodide(JC-1) probe.Western blot was used to detect the expression of B-cell lymphoma 2(Bcl-2),Bcl-2 associated X protein(Bax),cytochrome c(Cyt c),and cleaved cysteine proteinase-3(caspase-3) in the cells.RESULTS Compared with the L-OHP treatment group,the viability of colorectal cancer cells in the SchA + L-OHP treatment group was significantly decreased,while apoptosis was significantly increased.SchA could enhance ROS accumulation,Bax and cleaved caspase-3 expression,and mitochondrial Cyt c release,and decrease Bcl-2 expression in colorectal cancer cells induced by L-OHP.CONCLUSION SchA enhances the killing effect of L-OHP on colorectal cancer cells,and the mechanism may be related to the enhancement of intracellular ROS accumulation and the expression of apoptosis-related proteins.
作者 易弼顺 马柏强 李冰震 邢永俊 Bi-Shun Yi;Bai-Qiang Ma;Bing-Zhen Li;Yong-Jun Xing(Department of Trauma,Acute Abdomen,Hernia Surgery and Abdominal Surgery,Lishui City People’s,Hospital Lishui 323000,Zhejiang Province,China)
出处 《世界华人消化杂志》 CAS 2022年第21期956-963,共8页 World Chinese Journal of Digestology
关键词 五味子甲素 奥沙利铂 结直肠癌 化疗敏感性 Schizandrin A Oxaliplatin Colorectal cancer Chemosensitivity
  • 相关文献

参考文献1

二级参考文献61

  • 1Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, RebeloM, Parkin DM, Forman D, Bray F. Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI:10.1002/ijc.29210].
  • 2Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction ofcancer incidence and mortality in Korea, 2014. Cancer Res Treat 2014;46: 124-130 [PMID: 24851103 DOI: 10.4143/crt.2014.46.2.124].
  • 3van Steenbergen LN, Elferink MA, Krijnen P, Lemmens VE,Siesling S, Rutten HJ, Richel DJ, Karim-Kos HE, Coebergh JW.Improved survival of colon cancer due to improved treatment anddetection: a nationwide population-based study in The Netherlands1989-2006. Ann Oncol 2010; 21: 2206-2212 [PMID: 20439339DOI: 10.1093/annonc/mdq227].
  • 4Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M,Allemani C, Colonna M, Grande E, Grosclaude P, Vercelli M. Thecancer survival gap between elderly and middle-aged patients inEurope is widening. Eur J Cancer 2009; 45: 1006-1016 [PMID:19121578 DOI: 10.1016/j.ejca.2008.11.028].
  • 5Surgery for colorectal cancer in elderly patients: a systematicreview. Colorectal Cancer Collaborative Group. Lancet 2000; 356:968-974 [PMID: 11041397 DOI: 10.1016/S0140-6736(00)02713-6].
  • 6Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age,sex, and racial differences in the use of standard adjuvant therapyfor colorectal cancer. J Clin Oncol 2002; 20: 1192-1202 [PMID:11870160].
  • 7Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF,Neugut AI. Survival associated with 5-fluorouracil-based adjuvantchemotherapy among elderly patients with node-positive coloncancer. Ann Intern Med 2002; 136: 349-357 [PMID: 11874307DOI: 10.7326/0003-4819-136-5-200203050-00007].
  • 8Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvantchemotherapy use after surgery for stage III colon cancer. J NatlCancer Inst 2001; 93: 850-857 [PMID: 11390534 DOI: 10.1093/jnci/93.11.850].
  • 9Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D,Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC. Half of elderlypatients routinely treated for colorectal cancer receive a substandardtreatment. Crit Rev Oncol Hematol 2009; 71: 249-257[PMID: 19131256 DOI: 10.1016/j.critrevonc.2008.11.006].
  • 10van Erning FN, van Steenbergen LN, Lemmens VE, Rutten HJ,Martijn H, van Spronsen DJ, Janssen-Heijnen ML. Conditionalsurvival for long-term colorectal cancer survivors in theNetherlands: who do best- Eur J Cancer 2014; 50: 1731-1739[PMID: 24814358 DOI: 10.1016/j.ejca.2014.04.009].

共引文献22

同被引文献13

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部